Advertisement
Research Article

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

  • Heidi Greulich mail,

    To whom correspondence should be addressed. E-mail: heidig@broad.mit.edu (HG); E-mail: William_Sellers@dfci.harvard.edu (WRS); E-mail: Matthew_Meyerson@dfci.harvard.edu (MM)

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

    X
  • Tzu-Hsiu Chen,

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

    X
  • Whei Feng,

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

    X
  • Pasi A Jänne,

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • James V Alvarez,

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Mauro Zappaterra,

    Affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

    X
  • Sara E Bulmer,

    Affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

    X
  • David A Frank,

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • William C Hahn,

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America, Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • William R Sellers mail,

    To whom correspondence should be addressed. E-mail: heidig@broad.mit.edu (HG); E-mail: William_Sellers@dfci.harvard.edu (WRS); E-mail: Matthew_Meyerson@dfci.harvard.edu (MM)

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

    X
  • Matthew Meyerson mail

    To whom correspondence should be addressed. E-mail: heidig@broad.mit.edu (HG); E-mail: William_Sellers@dfci.harvard.edu (WRS); E-mail: Matthew_Meyerson@dfci.harvard.edu (MM)

    Affiliations: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America, Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Published: October 04, 2005
  • DOI: 10.1371/journal.pmed.0020313

Reader Comments (1)

Post a new comment on this article